IRVINE, CA, and HERSTAL, BELGIUM, June 14, 2015 – MDxHealth SA (Euronext: MDXH), announced today, the appointment of Philip J. Ginsburg, MD, as Chief Medical Officer (CMO). Dr. Ginsburg joins the company with over 20 years of commercial medical laboratory and urology experience. In this new role, Dr. Ginsburg will have overall responsibility for clinical strategy, including scientific and clinical affairs.
"Philip is a valuable addition to the MDxHealth team; with an excellent pedigree in the diagnostics and urology sectors and an entrepreneurial approach, we are confident he will immediately contribute to our on-going growth and success," noted Dr. Jan Groen, CEO of MDxHealth. "Philip's depth of medical and diagnostic experience rounds out our management team as we continue to execute on our commercialization strategy for ConfirmMDx in the US urology community and as we develop additional epigenetic tests for the urology market."
"This is an exciting time to join MDxHealth, especially following a capital increase which enables the company to accelerate its commercial efforts and build its leading position within the urology community," stated Dr. Ginsburg. My role will be to expand upon the solid foundation MDxHealth has achieved with ConfirmMDx, explore expanded indications for the test in prostate cancer detection and prognosis, as well as validation and commercialization of promising new products in the pipeline."
Before joining MDxHealth, Dr. Ginsburg was CMO, at Toma Biosciences, Iris International, Inc. and President of Arista, a personalized medicine division of Iris acquired by Beckman Coulter a subsidiary of Danaher Corporation. Prior to Iris International, Dr. Ginsburg was Chief Executive Officer, co-founder and CMO of AlliedPath, a CLIA molecular diagnostic laboratory focussing on urology, which was ultimately acquired by Iris International in July 2010. Dr. Ginsburg also served as Senior Medical Director at Gen-Probe, Inc., where he was involved with the clinical development program for their PCA3 test for prostate cancer detection and formerly served as a medical director at Quest Diagnostics.
Dr. Ginsburg earned his medical degree at the University of Pretoria School of Medicine, South Africa, later specializing in clinical pathology at the University of Witwatersrand and the South African Institute of Medical Research.
About ConfirmMDx® for Prostate Cancer
Over 975,000 American men are diagnosed with a negative prostate biopsy each year; however approximately 25-35% of those men receive false-negative results. Under the current standard of care, prostate biopsy procedures consisting of 10-12 needle biopsy cores only sample approximately 1% of a man's prostate. This approach leaves men at risk of undetected cancer, leading to a high rate of repeat biopsies, even on cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This "halo" around a cancer lesion can be present despite cells having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying truly negative men who may forego an unnecessary repeat biopsy procedure. Performance of the proprietary ConfirmMDx genes and technology has been published in 45 studies on over 5,000 patients tested. The ConfirmMDx test has qualified for Medicare reimbursement as of November 3, 2014 and is also available to more than 152 million insured lives via private health insurance plans.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
Mike Sinclair (PR)
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075
Amber Fennell (IR)
Consillium
UK: +44 20 3709 5701
Cell: + 44 7739658783
This press release may contain forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.